Patents Assigned to Endo Pharmaceuticals, Inc.
-
Patent number: 8729079Abstract: The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and R1 and R2 are defined herein.Type: GrantFiled: August 23, 2012Date of Patent: May 20, 2014Assignee: Endo Pharmaceuticals Inc.Inventors: Aranapakam Venkatesan, Roger Astbury Smith, Subramanya Hosahalli, Vijay Potluri, Sunil Kumar Panigrahi, Vishnu Basetti, Karunasree Kunta
-
Patent number: 8685418Abstract: The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.Type: GrantFiled: October 24, 2012Date of Patent: April 1, 2014Assignee: Endo Pharmaceuticals Inc.Inventors: Scott Kevin Thompson, Roger Astbury Smith, Sandeep Gupta, Tony Priestley, Nicholas James Laping, Ashis K. Saha, Sonali Rudra
-
Patent number: 8679535Abstract: Disclosed are sustained release oral solid dosage forms comprising a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l; a pH modifying agent; and a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, said dosage form providing a sustained release of said medicament after oral administration to human patients.Type: GrantFiled: March 27, 2007Date of Patent: March 25, 2014Assignee: Endo Pharmaceuticals Inc.Inventors: Anand R. Baichwal, Troy W. McCall, Lirong Liu, Steve Labudzinski
-
Publication number: 20140073782Abstract: The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: ApplicationFiled: November 11, 2013Publication date: March 13, 2014Applicant: Endo Pharmaceuticals Inc.Inventors: Roger A. Smith, Scott Kevin Thompson, Subramanya Hosahalli, Mallesham Bejugam, Srinivas Nanduri, Sunil Kumar Panigrahi, Natarajan Mahalingam
-
Publication number: 20140051702Abstract: The present application provides methods of using the aminoindane compounds of formula (I) or (II) in treating an overactive bladder or interstitial cystitis by administering one or more of the compounds to a patient.Type: ApplicationFiled: August 15, 2013Publication date: February 20, 2014Applicant: Endo Pharmaceuticals Inc.Inventors: Sandeep Gupta, Tony Priestley, Nicholas James Laping
-
Publication number: 20140038952Abstract: The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: ApplicationFiled: August 2, 2013Publication date: February 6, 2014Applicant: Endo Pharmaceuticals Inc.Inventors: Roger Astbury Smith, Aranapakam Venkatesan, Mallesham Bejugam, Subramanya Hoshalli, Srinivas Nanduri
-
Publication number: 20130324975Abstract: A valve having a valve body with a first end, a second end, a longitudinal axis extending between the first end and the second end, and an inclined sliding surface having a longitudinal slot therein. The valve also includes a tubular member with walls defining a passageway extending through the valve body from the first end to the second end; and a slidable member mounted on the valve body and moveable between a first position and a second position. The slidable member is adapted to urge walls of the tubular member towards mutual contact when moved from the first position to the second position.Type: ApplicationFiled: May 31, 2012Publication date: December 5, 2013Applicant: ENDO PHARMACEUTICALS INC.Inventors: Peter F. Douglas, Emily Y. Ho, Vinu J. Zachariah, Arvind Mathivathanan, Arpita Banerjee, Sanjeeb K. Behera, Kiran P. Devapalan, Michael C. Mochahari, Rajkumar Palanivel, Gopinath Ravindranath, Muthamizhselvan Muthusamy
-
Publication number: 20130209561Abstract: We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.Type: ApplicationFiled: February 21, 2013Publication date: August 15, 2013Applicant: Endo Pharmaceuticals Inc.Inventor: Endo Pharmaceuticals Inc.
-
Publication number: 20130190492Abstract: The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: ApplicationFiled: March 7, 2013Publication date: July 25, 2013Applicant: Endo Pharmaceuticals Inc.Inventor: Endo Pharmaceuticals Inc.
-
Publication number: 20130172382Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as an immediate release product as a single dose. The controlled release nature of the tablet prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.Type: ApplicationFiled: February 26, 2013Publication date: July 4, 2013Applicant: Endo Pharmaceuticals Inc.Inventor: Endo Pharmaceuticals Inc.
-
Patent number: 8440662Abstract: The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: GrantFiled: October 31, 2011Date of Patent: May 14, 2013Assignee: Endo Pharmaceuticals, Inc.Inventors: Roger Astbury Smith, Scott Kevin Thompson, Subramanya Hosahalli, Mallesham Bejugam, Srinivas Nanduri, Sunil Kumar Panigrahi, Natarajan Mahalingam
-
Publication number: 20130101667Abstract: The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.Type: ApplicationFiled: October 24, 2012Publication date: April 25, 2013Applicant: ENDO PHARMACEUTICALS, INC.Inventor: Endo Pharmaceuticals, Inc.
-
Publication number: 20130085148Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CPY17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.Type: ApplicationFiled: September 30, 2012Publication date: April 4, 2013Applicant: ENDO PHARMACEUTICALS INC.Inventor: Endo Pharmaceuticals Inc.
-
Publication number: 20130085164Abstract: The present application provides novel imidazole compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CPY17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.Type: ApplicationFiled: September 30, 2012Publication date: April 4, 2013Applicant: ENDO PHARMACEUTICALS INC.Inventor: Endo Pharmaceuticals Inc.
-
Publication number: 20130053346Abstract: The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and R1 and R2 are defined herein.Type: ApplicationFiled: August 23, 2012Publication date: February 28, 2013Applicant: Endo Pharmaceuticals IncInventors: Aranapakam Venkatesan, Roger Astbury Smith, Subramanya Hosahalli, Vijay Potluri, Sunil Kumar Panigrahi, Vishnu Basetti, Karunasree Kunta
-
Patent number: 8329216Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.Type: GrantFiled: June 29, 2006Date of Patent: December 11, 2012Assignee: Endo Pharmaceuticals Inc.Inventors: Haui-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
-
Patent number: 8309122Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.Type: GrantFiled: February 28, 2007Date of Patent: November 13, 2012Assignee: Endo Pharmaceuticals Inc.Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
-
Publication number: 20120252832Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as an immediate release product as a single dose. The controlled release nature of the tablet prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.Type: ApplicationFiled: June 12, 2012Publication date: October 4, 2012Applicant: Endo Pharmaceuticals Inc.Inventors: Frank S. Caruso, Huai-Hung Kao
-
Publication number: 20120245606Abstract: Provided herein is a two-part coupling assembly for re-connecting a first hollow body part to a second body part and an instrument and method for emplacement. The coupling assembly comprises coupling parts having securement elements that are actuated by separate deployment mechanisms of the instrument and attach to the first and second body parts. The first and second coupling parts having interconnecting elements that couple the two-part assembly together and re-connect the first and second body parts.Type: ApplicationFiled: March 20, 2012Publication date: September 27, 2012Applicant: ENDO PHARMACEUTICALS INC.Inventors: Roger P. Goldberg, Douglas S. Scherr
-
Publication number: 20120237603Abstract: We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.Type: ApplicationFiled: May 25, 2012Publication date: September 20, 2012Applicant: Endo Pharmaceuticals Inc.Inventors: Huai-Hung Kao, Yadi Zeng, Michelle Howard-Sparks, Fai Jim